Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2301 January 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Initial application Applications only from a haematologist. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate)		
Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, high risk chronic phase, or in chronic phase		
Patient has documented CML treatment failure* with a tyrosine kinase inhibitor (TKI) or Patient has experienced treatment limiting toxicity with a tyrosine kinase inhibitor (TKI) precluding further treatment		
and Maximum nilotinib dose of 800 mg/day and Subsidised for use as monotherapy only		
Note: *treatment failure as defined by Leukaemia Net Guidelines.		
Renewal Current approval Number (if known):		
Prerequisites(tick boxes where appropriate)		
Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines		
Nilotinib treatment remains appropriate and the patient is benefiting from treatment		
Maximum nilotinib dose of 800 mg/day		
Subsidised for use as monotherapy only		

I confirm the above details are correct and that in signing this form I understand I may be audited.